Fieldfisher has merged with Beijing boutique JS Partners under a Swiss verein, making it the latest international law firm to gain Chinese law capability.
JS Partners, which will will adopt the Fieldfisher brand, has made several partner hires ahead of the tie-up, notably antitrust partner Zhaofeng Zhou, who joined as managing partner this July from Bird & Bird’s Beijing office. According to Zhou, the firm also has plans to open a Shanghai office soon.
In addition to antitrust and intellectual property, the 12-partner firm advises on cross-border commercial law including corporate, finance, tax and dispute resolution. It was founded in 2008 by partner Liu Jinshi, who specialises in Japan and Korea work.
Three years ago, Fieldfisher secured a presence in Shanghai through a Swiss verein combination with three-partner firm Ryser & Associates. However, that tie-up has since ended.
In a statement, Fieldfisher managing partner Michael Chissick said: “Our relationship with Ryser & Associates has, for the last three years, been of great value to the firm. However, as Fieldfisher continues to grow it became apparent that we need a larger partner in China. As such, we mutually agreed to end the relationship but retain a good working relationship with the firm.”
Under the verein structure, Fieldfisher will operate as a licensed Chinese law firm, with access to all aspects of Chinese legal practice. The setup was pioneered in 2012 by legacy King & Wood when it merged with Australian firm Mallesons Stephen Jaques. Last year, the same structure was used by Dentons when it merged with Beijing-based Dacheng.
Full content: Legal Week
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas